$NOVO News
Last published 1y ago
- 1y agoMTSRNOVOMetsera Receives Amended Proposal from Novo Nordisk; Metsera Declares Novo Nordisk Amended Proposal "Superior"PR NewswireMetsera, Inc. (NASDAQ: MTSR) ("Metsera") today announced that its Board of Directors had determined, after consultation with its outside counsel and...
- 1y agoMTSRNOVOMetsera Receives Unsolicited Proposal from Novo NordiskPR NewswireMetsera, Inc. (NASDAQ: MTSR) ("Metsera") today announced that its Board of Directors had determined, after consultation with its outside counsel and...
- 1y agoNOVOSHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo NordiskGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Novo To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in
- 2y agoALGSHAENVOPLRX+2Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical OfficerGlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies
- 5y agoGILDNOVOGilead and Novo Nordisk Expand NASH Clinical CollaborationBusiness WireFOSTER CITY, Calif. & BAGSVÆRD, Denmark--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Novo Nordisk A/S (Nasdaq Copenhagen: NOVO B) today announced that the companies have expanded their clinical collaboration in non-alcoholic steatohepatitis (NASH).
- 5y agoGILDNOVOGilead and Novo Nordisk Present New Data from Proof-of-Concept Trial in NASHBusiness WireFOSTER CITY, Calif. & BAGSVÆRD, Denmark--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Novo Nordisk A/S (NASDAQ Copenhagen: NOVO B) today announced results from a Phase 2 proof-of-concept trial. The five-arm trial evaluated combinations of Novo Nordisk’s semaglutide, a GLP-1 receptor agonist, with Gilead’s investigational FXR agonist cilofexor and/or Gilead’s investigational ACC inhibi ...